Atara Biotherap (ATRA)

$6.57 -1.26 (-16.09%)
Market Cap 75.80M
Revenue (ttm) 8.57M
Net Income (ttm) -276.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,222.05%
Debt to Equity Ratio 0.00
Volume 933,900
Avg Vol 173,004
Day's Range N/A - N/A
Shares Out 5.76M
Stochastic %K 11%
Beta 0.51
Analysts Sell
Price Target $17.00

Latest News on ATRA

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:41 AM EST - 1 day ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Jan 16, 2025, 8:30 AM EST - 1 day ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Nov 27, 2024, 4:01 PM EST - 7 weeks ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Nov 13, 2024, 4:01 PM EST - 2 months ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Nov 12, 2024, 4:01 PM EST - 2 months ago

Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Nov 5, 2024, 4:01 PM EST - 2 months ago

Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 4, 2024, 4:01 PM EDT - 3 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 4:01 PM EDT - 4 months ago

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Sep 3, 2024, 4:16 PM EDT - 4 months ago

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Aug 12, 2024, 5:00 PM EDT - 5 months ago

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 4:01 PM EDT - 5 months ago

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 17, 2024, 9:00 AM EDT - 6 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Jul 3, 2024, 7:57 PM EDT - 7 months ago

Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 3, 2024, 1:39 PM EDT - 7 months ago

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Jun 21, 2024, 4:01 PM EDT - 7 months ago

Atara Biotherapeutics' Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Jun 17, 2024, 8:00 AM EDT - 7 months ago

Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 4:01 PM EDT - 8 months ago

Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

May 29, 2024, 4:01 PM EDT - 8 months ago

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

May 20, 2024, 9:25 AM EDT - 8 months ago

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

May 9, 2024, 4:01 PM EDT - 9 months ago

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Mar 28, 2024, 8:30 AM EDT - 10 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Feb 29, 2024, 9:05 AM EST - 11 months ago

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:30 PM EST - 11 months ago

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Feb 14, 2024, 9:00 AM EST - 1 year ago

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 5, 2024, 7:24 PM EST - 1 year ago

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Jan 31, 2024, 6:30 PM EST - 1 year ago

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Jan 8, 2024, 9:00 AM EST - 1 year ago

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 8, 2024, 8:00 AM EST - 1 year ago

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024, 4:01 PM EST - 1 year ago

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Dec 20, 2023, 4:01 PM EST - 1 year ago

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Dec 11, 2023, 12:00 PM EST - 1 year ago

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 1, 2023, 4:01 PM EST - 1 year ago

Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Nov 29, 2023, 6:05 PM EST - 1 year ago

Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Nov 22, 2023, 4:01 PM EST - 1 year ago

Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference

Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity

Nov 13, 2023, 2:13 AM EST - 1 year ago

Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Nov 10, 2023, 4:01 PM EST - 1 year ago

Atara Biotherapeutics To Participate at the Stifel Healthcare Conference

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Nov 8, 2023, 5:35 PM EST - 1 year ago

Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

Nov 4, 2023, 11:45 AM EDT - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Nov 1, 2023, 8:30 AM EDT - 1 year ago

Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability

Sep 19, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability

Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference

Aug 31, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference

Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout

Aug 21, 2023, 9:02 AM EDT - 1 year ago

Atara Biotherapeutics: A Speculative Buy On Upcoming Phase 2 Multiple Sclerosis Readout

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

Aug 8, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Aug 1, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Jul 31, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Jun 7, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023

Jun 5, 2023, 9:00 AM EDT - 1 year ago

Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023

Atara: MS Study Data Release And Other Catalysts Make This A Must Watch

May 11, 2023, 7:10 PM EDT - 1 year ago

Atara: MS Study Data Release And Other Catalysts Make This A Must Watch

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

May 8, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress

Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023

May 1, 2023, 4:01 PM EDT - 1 year ago

Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023